24,493 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by SG Americas Securities LLC

SG Americas Securities LLC bought a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 24,493 shares of the company's stock, valued at approximately $388,000. SG Americas Securities LLC owned approximately 0.06% of Keros Therapeutics as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Point72 Asset Management L.P. boosted its position in Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock valued at $55,025,000 after buying an additional 577,220 shares in the last quarter. Alkeon Capital Management LLC raised its stake in shares of Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock valued at $110,194,000 after acquiring an additional 298,694 shares during the last quarter. Parkman Healthcare Partners LLC boosted its holdings in shares of Keros Therapeutics by 112.3% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company's stock worth $24,493,000 after acquiring an additional 223,155 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Keros Therapeutics by 814.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 223,704 shares of the company's stock valued at $12,990,000 after purchasing an additional 199,245 shares in the last quarter. Finally, FMR LLC raised its position in Keros Therapeutics by 3.8% in the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company's stock valued at $284,493,000 after purchasing an additional 179,374 shares during the last quarter. Institutional investors own 71.56% of the company's stock.

Keros Therapeutics Price Performance

Shares of NASDAQ KROS traded down $0.66 during midday trading on Friday, reaching $10.86. 1,187,598 shares of the stock were exchanged, compared to its average volume of 1,945,047. The business has a 50-day simple moving average of $23.25 and a two-hundred day simple moving average of $43.79. The company has a market capitalization of $439.91 million, a price-to-earnings ratio of -2.08 and a beta of 1.39. Keros Therapeutics, Inc. has a 12 month low of $9.77 and a 12 month high of $73.00.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company had revenue of $0.39 million for the quarter. During the same quarter in the prior year, the business earned ($1.33) EPS. The business's revenue for the quarter was up 4750.0% on a year-over-year basis. Equities research analysts expect that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KROS has been the topic of several research analyst reports. HC Wainwright decreased their target price on Keros Therapeutics from $100.00 to $47.00 and set a "buy" rating on the stock in a report on Friday, December 13th. BTIG Research lowered shares of Keros Therapeutics from a "buy" rating to a "neutral" rating in a report on Thursday, December 12th. Cantor Fitzgerald downgraded shares of Keros Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Tuesday, January 21st. William Blair cut Keros Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Thursday, December 12th. Finally, TD Cowen lowered Keros Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Six research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $52.56.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.